HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, Sept. 29, 2015 (HealthDay News) -- Eudaimonic well-being is associated with lower tumor norepinephrine (NE) in women with epithelial ovarian cancer, according to a study published in the Oct. 1 issue of Cancer.
Lauren Z. Davis, from the University of Iowa in Iowa City, and colleagues assessed how two different aspects of well-being (eudaimonic and positive affect) and psychological distress were associated with tumor NE in 365 patients with ovarian cancer. High-performance liquid chromatography with electrochemical detection was used to measure tumor NE in frozen tissue samples.
The researchers found that eudaimonic well-being, positive affect, and psychological distress modeled as distinct, but correlated constructs. A good model fit was found for structural equation modeling analysis that included physical well-being, stage of disease, histology, psychological treatment history, beta-blocker use, and caffeine use as covariates. This model demonstrated that eudaimonic well-being was related to lower tumor NE (P = 0.045), while no effects were found for positive affect or psychological distress.
"Because adrenergic signaling is implicated in tumor progression, increasing eudaimonic well-being may improve both psychological and physiologic resilience in patients with ovarian cancer," the authors write.
Two authors disclosed financial ties to the medical device industry.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 31, 2022